Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy.
Journal
HemaSphere
ISSN: 2572-9241
Titre abrégé: Hemasphere
Pays: United States
ID NLM: 101740619
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
26
07
2022
accepted:
17
11
2022
entrez:
26
1
2023
pubmed:
27
1
2023
medline:
27
1
2023
Statut:
epublish
Résumé
The introduction of chimeric antigen receptor (CAR) T-cell therapy has led to a fundamental shift in the management of relapsed and refractory large B-cell lymphoma. However, our understanding of risk factors associated with non-response is still insufficient and the search for predictive biomarkers continues. Some parameters measurable on
Identifiants
pubmed: 36698613
doi: 10.1097/HS9.0000000000000817
pmc: PMC9829285
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e817Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Références
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
J Clin Oncol. 2020 Sep 20;38(27):3119-3128
pubmed: 32401634
Blood Adv. 2021 Mar 9;5(5):1283-1290
pubmed: 33651099
Blood. 2021 May 13;137(19):2621-2633
pubmed: 33512407
Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3550-3559
pubmed: 33928400
Am J Hematol. 2020 Nov;95(11):1324-1333
pubmed: 32744738
J Exp Med. 1997 Jul 7;186(1):47-55
pubmed: 9206996
Front Oncol. 2021 Aug 04;11:713577
pubmed: 34422666
Ann Hematol. 2021 Sep;100(9):2303-2310
pubmed: 34236497
Radiology. 1997 Jun;203(3):795-800
pubmed: 9169707
Exp Hematol Oncol. 2021 Dec 9;10(1):55
pubmed: 34886908
Blood Adv. 2020 Jul 28;4(14):3268-3276
pubmed: 32702097
Eur J Cancer. 2020 Jan;124:25-36
pubmed: 31710995
J Clin Oncol. 2018 Jul 10;36(20):2024-2034
pubmed: 29750632
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Nucl Med Commun. 2021 Mar 1;42(3):284-291
pubmed: 33306623
J Immunother Cancer. 2018 Jun 15;6(1):56
pubmed: 29907163
Haematologica. 2022 Jul 01;107(7):1633-1642
pubmed: 34407602
Br J Haematol. 2021 Nov;195(3):405-412
pubmed: 34500492
Ann Oncol. 2021 Mar;32(3):404-411
pubmed: 33278600
Ann Oncol. 2006 Jan;17(1):117-22
pubmed: 16192294
Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):953-962
pubmed: 34480603
J Clin Invest. 2012 Mar;122(3):899-910
pubmed: 22293174
Blood Adv. 2020 Oct 13;4(19):4898-4911
pubmed: 33035333
Clin Nucl Med. 2021 Aug 1;46(8):627-634
pubmed: 34115706
J Nucl Med. 2021 Mar;62(3):332-337
pubmed: 32680929
N Engl J Med. 2022 Feb 17;386(7):640-654
pubmed: 34891224
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1209-19
pubmed: 26902371
Blood Adv. 2020 Nov 24;4(22):5607-5615
pubmed: 33180899